How it works
It's a single molecule that activates three receptors — GLP-1, GIP, and glucagon. The GLP-1/GIP arms curb appetite and blood sugar; adding glucagon-receptor activity is thought to also raise energy expenditure. See tirzepatide (dual) for the step below it.
The evidence
Phase 3 results reported by Lilly and covered in the press describe average weight loss in the high-20s percent (with even higher figures in extension cohorts) — the largest of the mainstream incretin class so far. Those results come from supervised trials with gradual escalation, not the top dose from day one.
Safety
The side-effect profile overlaps the rest of the class — predominantly gastrointestinal, dose-dependent — plus monitoring of heart rate and glucose given the glucagon activity. Read the GLP-1 side-effects article for the warning signs; they apply here.
FAQ
Tirzepatide hits two receptors (GLP-1 + GIP); retatrutide adds glucagon for a third, giving a broader metabolic footprint.
No — it's investigational and not FDA-approved as of writing. Status changes, so verify current information.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Retatrutide: what is it and is it FDA approved? (Drugs.com)
- Lilly Phase 3 retatrutide results (investor release)
- Next-gen weight-loss drug retatrutide trial (Scientific American)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Frank — part of the PepConnection crew.